Jerusalem, Israel.

NovellusDx announced that the EU Patent Office granted it a patent for: “METHODS FOR DETERMINING DRUG RESPONSE OF PATIENT SPECIFIC MUTATIONS” . The patent, part of a large patent family, is fully owned by the company and protects its core technology.

The methods disclosed in the patent relate to the functionally testing mutations and their response to drugs using the FACT test.
“This patent is part of our main patent family”, says Dr. Tarcic, “and protects the main kernel of our system to identify driver mutations by examining their effect in live cells”.